Hasegawa S, Nakashima J, Nakashima Y, Nakamura S, Kimura S
Department of Urology, Second Tokyo National Hospital.
Hinyokika Kiyo. 1987 Dec;33(12):2055-8.
Serum gamma-seminoprotein (gamma-Sm) in patients with prostatic disease was determined by enzyme immunoassay. A total of 136 patients including 13 untreated and 40 treated patients with prostatic cancer, 45 patients with benign prostatic hyperplasia (BPH) and 38 patients with other urological diseases were analyzed. The mean +/- SD of serum gamma-Sm in the 13 patients with untreated prostatic cancer and the 45 patients with BPH was 31.7 +/- 46.1 and 3.7 +/- 6.6 ng/ml, respectively, there being a statistically significant difference between the two groups. All patients with untreated stage A or B prostatic cancer had a serum gamma-Sm of less than 4 ng/ml (cut off value). The mean level of serum gamma-Sm was 5.1 +/- 1.9 ng/ml for all patients with untreated stage C prostatic cancer; 66% of them had a value above the cut off value. However, it was 55.9 +/- 52.6 ng/ml in all patients with untreated stage D prostatic cancer; 87.5% of them had a value above the cut-off value. These results suggest that gamma-Sm may be a useful tumor marker in the management of patients with prostatic cancer.
采用酶免疫分析法测定前列腺疾病患者血清γ-精蛋白（γ-Sm）。共分析了136例患者，其中包括13例未经治疗的前列腺癌患者、40例接受过治疗的前列腺癌患者、45例良性前列腺增生（BPH）患者和38例其他泌尿系统疾病患者。13例未经治疗的前列腺癌患者和45例BPH患者血清γ-Sm的平均值±标准差分别为31.7±46.1和3.7±6.6 ng/ml，两组之间存在统计学显著差异。所有未经治疗的A期或B期前列腺癌患者血清γ-Sm均低于4 ng/ml（临界值）。所有未经治疗的C期前列腺癌患者血清γ-Sm的平均水平为5.1±1.9 ng/ml；其中66%的值高于临界值。然而，所有未经治疗的D期前列腺癌患者血清γ-Sm为55.9±52.6 ng/ml；其中87.5%的值高于临界值。这些结果表明，γ-Sm可能是前列腺癌患者管理中的一种有用的肿瘤标志物。
